Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.
Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. · 2013
Read Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. by Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3898468.txt.
Introduction
In Cell in 2013, Filipe Cabreiro and co-authors report a worm aging study. Metformin, the world's top diabetes drug, extends life in the worm C. elegans kept with E. coli bacteria. How it acts is unsettled. The worm's bacterial food shapes its health, so the team look there first.
The drug changed the bacteria's folate and methionine chemistry, which in turn put the worm into a state like methionine restriction, a known life extender. Worm gene faults in that same pathway altered the drug's effect, backing the chain. Depending on the bacterial strain and sugar level, the drug could lengthen or shorten worm life. The work hints that gut microbe shifts may drive both gains and gut side effects in people.
Catalog record
| CREATOR | Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, Weinkove D, Schuster E, Greene ND, Gems D. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism By Filipe Cabreiro, Catherine Au, Kit-Yi Leung, Nuria Vergara-Irigaray, Helena M Cochemé, Tahereh Noori, David Weinkove, Eugene Schuster, Nicholas DE Greene, David Gems Published in: Cell DOI: 10.1016/j.cell.2013.02.035 ABSTRACT Summary The biguanide drug metformin is widely prescribed to treat type 2 diabetes and metabolic syndrome, but its mode of action remains uncertain. Metformin also increases lifespan in Caenorhabditis elegans cocultured with Escherichia coli. This bacterium exerts complex nutritional and pathogenic effects on its nematode predator/host that impact health and aging. We report that metformin increases lifespan by altering microbial folate and methionine metabolism. Alterations in metformin-induced longevity by mutation of worm methionine synthase (metr-1) and S-adenosylmethionine synthase (sams-1) imply metformin-induced methionine restriction in the host, consistent with action of this drug as a dietary restriction mimetic. Metformin increases or decreases worm lifespan, depending on E. coli strain metformin sensitivity and glucose concentration. In mammals, the intestinal microbiome influences host metabolism, including development of metabolic disease. Thus, metformin-induced alteration of microbial metabolism could contribute to therapeutic efficacy—and also to its side effects, which include folate deficiency and gastrointestinal upset. PaperClip INTRODUCTION Metformin is the world’s most widely prescribed drug, as an oral antihyperglycemic agent for type 2 diabetes (T2D) and in the treatment of metabolic syndrome. However, the real and potential benefits of metformin therapy go beyond its prescribed usage, including reduced risk of cancer (Dowling et al., 2011) and, in animal models, delayed aging, an effect seen in rodents (Anisimov et al., 2011) and in the nematode Caenorhabditis elegans (Onken and Driscoll, 2010). The mechanisms underlying these positive effects remain unclear. One possibility is that metformin recapitulates the effects of dietary restriction (DR), the controlled reduction of food intake that can improve late-life health and increases lifespan in organisms ranging from nematodes and fruit flies to rodents and rhesus monkeys (Mair and Dillin, 2008). In mammals, the action of metformin is partly mediated by AMPK activation, which results in downregulation of TOR and the IGF-1/AKT pathways to reduce energy-consuming processes (Pierotti et al., 2012). An unexplored possibility is that metformin alters mammalian physiology via its effects on gut microbiota (Bytzer et al., 2001). The gut microbiome (or microbiota) plays a major role in the effects of nutrition on host metabolic status (Nicholson et al., 2012), as well as contributing to metabolic disorders such as obesity, diabetes, metabolic syndrome, autoimmune disorders, inflammatory bowel disease, liver disease, and cancer (Delzenne and Cani, 2011; Kau et al., 2011; Nicholson et al., 2012). It may also influence the aging process (Ottaviani et al., 2011). It has been argued that the host and its symbiotic microbiome acting in association (holobiont) should be considered as a unit of selection in evolution (Zilber-Rosenberg and Rosenberg, 2008). Coevolution of microbiota facilitates host adaptation by enabling e.g., nutrient acquisition, vitamin synthesis, xenobiotic detoxification, immunomodulation, and gastrointestinal maturation. In return, the host provides a sheltered incubator with nutrients (Bäckhed et al., 2005). Thus, the two components of the holobiont are symbiotic, but microbiota can also be commensal or pathogenic. Defining interactions between drug therapy, microbiome and host physiology is experimentally challenging given the complex and heterogeneous nature of mammalian gut microbiota. Here simple animal models amenable to genetic manipulation can be helpful. For example, in the fruit fly Drosophila, microbiota modulates host development and metabolic homeostasis via the TOR pathway (Storelli et al., 2011). C. elegans is particularly convenient for such studies because under standard culture conditions only a single microbe is present (as a food source): the human gut bacterium Escherichia coli (Brenner, 1974). Active bacterial metabolism is a critical nutritional requirement for C. elegans, the absence of which retards development and extends lifespan (Lenaerts et al., 2008). Moreover, worms are sometimes long-lived on mutant E. coli with metabolic defects (Saiki et al., 2008; Virk et al., 2012) and on microbial species thought to enhance human health, e.g., from the genera Lactobacillus and Bifidobacterium (Ikeda et al., 2007). These observations suggest that E. coli plays a more active role in C. elegans nutrition and metabolism than as a mere food source, and in some respects acts as microbiota (Lenaerts et al., 2008). C. elegans has also been used extensively to identify genes that specify endocrine, metabolic, and dietary regulation of aging (Kenyon, 2010). In this study, we examine the mechanism by which metformin extends lifespan in C. elegans. We report that its effects are mediated by the cocultured E. coli, where metformin inhibits bacterial folate and methionine metabolism. This, in turn, leads to altered methionine metabolism in the worm, and increased lifespan. These findings reveal how drug action on host-microbiome interactions can impact health and longevity. RESULTS Extension of C. elegans Lifespan by Metformin Is Mediated by Live E. coli We first verified the effects on worm lifespan of metformin, and also the more potent biguanide drug phenformin. Metformin at 25, 50, and 100 mM increased mean lifespan by 18%, 36%, and 3% (Figure 1A; Table S1 available online). Phenformin at 1.5, 3, and 4.5 mM also increased lifespan, by 5%, 21%, and 26% (Figure 1B; Table S1). As expected, maximal effects on lifespan of these pharmacologically similar drugs were nonadditive (Figure 1C; Table S1). Metformin reduced the exponential age increase in mortality rate (Figure 1D), demonstrating that it slows aging (at least until day 18) rather than reducing risk of death. Metformin also modestly increased mean lifespan when administered from middle age onward, but only at 25 mM (+8%, p < 0.001; Figure 1E; Table S1). In most trials, the DNA replication inhibitor FUdR was used to prevent progeny production, but effects of metformin on lifespan are not FUdR-dependent (Figures S1F and S1G; Table S1) (Onken and Driscoll, 2010). These results confirm the robust effects of biguanide drugs on aging in C. elegans. [Figure: The Biguanide Drugs Phenformin and Metformin Decelerate Aging in C. elegans(A and B) Metformin (A) and phenformin (B) extend lifespan in a dose-dependent manner. Phenformin alters fecundity and reduces body size (see Figures S1A–S1D).(C) Phenformin (4.5 mM) does not increase lifespan in the presence of 50 mM metformin, consistent with similar mechanism of drug action.(D) Metformin decreases the exponential increase in age-related mortality (for survival curve see Figure S1E).(E) Later-life administration (day 8) of metformin increases lifespan at lower concentrations (25, but not 50 or 100 mM).See also Figure S1. For statistics, see Table S1.] [Figure: Effects of Biguanides on Fecundity, Growth, and Lifespan, Related to Figure 1(A) Dose-dependent reduction in daily fecundity by phenformin.(B) Effect of phenformin on daily fecundity as a proportion of total fecundity. Note the apparent, slight reproductive delay.(C) Dose-dependent reduction in brood size by phenformin.(D) Phenformin causes a reduction in body length (L4 stage).(E) Metformin robustly increases lifespan when administered from early adulthood onward. Combined data for all survival assays performed, and corresponding to mortality data in Figure 1D (dots represent confidence intervals). We also compared effects of metformin administered for 2 generations prior to the start of the survival assay with administration from the L4 stage onward, and detected no difference (Table S1).(F and G) Effects of metformin on lifespan are not affected by FUdR.For statistics see Table S1. Error bars, SEM. ∗p < 0.05;